Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.36 |
| ▸ | RXRB | P28702 | 12/20 | 0.36 |
| ▸ | RARB | P10826 | 9/20 | 0.36 |
| ▸ | RARG | P13631 | 9/20 | 0.36 |
| ▸ | RXRG | P48443 | 8/20 | 0.36 |
| ▸ | RARA | P10276 | 8/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.32 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31746176 | 0.73 | RARB (0.31) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL4564959 | 0.73 | RARB (0.31) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL31294415 | 0.72 | RARA (0.36) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL4970465 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL2237817 | 0.70 | RXRA (0.33) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL29853980 | 0.68 | NPC1 (0.31) | — | |
| SCHEMBL4324596 | 0.67 | — | — | |
| SCHEMBL2355383 | 0.66 | — | — | |
| SCHEMBL21244356 | 0.66 | RXRA (0.33) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL6908994 | 0.65 | RXRA (0.35) | RXRARXRBRARBRARGRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601666-B2 | Provide polymers having high molecular weight as well as good crystallinity preferably prepared at higher temperatures and productivities than otherwise possible | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1765841-B1 | OLEFIN POLYMERIZATION CATALYST SYSTEM AND PROCESS FOR USE THEREOF | EXXONMOBIL CHEM PATENTS INC (US) | 2008-10-08 | — | — | EP | disclosed |
| CN-101124235-A | Olefin polymerization catalyst system and method of using same | EXXONMOBIL CHEM PATENTS INC (US) | 2008-02-13 | — | — | CN | disclosed |
| US-20060009595-A1 | Olefin polymerization catalyst system and process for use thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009595-A1 | Olefin polymerization catalyst system and process for use thereof | OR10J3, CHRM2, CHRM1 | RXRA 1309/4885RXRB 1474/4885RARB 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.